Join US
Donate today Partner with us
Search

Meeting of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)

February 26, 2016 | Washington, D.C. (USA)

On March 14-15 2016, the U.S. Department of Health and Human Services will host a meeting of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) in Washington, D.C.

GloPID-R is a global research funding consortium with the goal to facilitate an effective research response within 48 hours of a significant outbreak. Until recently, there has been no platform for a network of research funders to identify and prepare the best solutions and channel the necessary funds in health crisis outbreaks. An international research funding collaboration allows national and local organizations to optimize valuable resources, avoid the duplication of efforts and save lost time.

At a time when President Obama and other countries are scrambling to combat the Zika virus, leading experts from Brazil, WHO and PAHO will present on the most current information on affected regions, the research already underway, and the latest and anticipated actions taken by research funding organizations.

Dr. Nicole Lurie, Assistant Secretary for Preparedness and Response (ASPR), will present on the Global Health Security Agenda (GHSA) and other major US actions in emergency response preparedness. International topics include: G7 Health Minister Summit, WHO Blueprint on R&D, and DAVOS Health Vaccine.

Key Presenters

  • Nicole Lurie, Assistant Secretary for Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS).

  • Line Matthiessen, Head of Unit ‘Fighting Infectious Diseases and Global Epidemics’, DG Research and Innovation, European Commission, and GloPID-R Interim Chair.

  • Marc Ouellette, Scientific Director, Institute of Infection and Immunity, Canadian Institutes of Health Research (CIHR).

  • Jeremy Farrar, Director of the Wellcome Trust.

  • Bernadette Murgue, Project Manager of the WHO R&D Blueprint.

From Ebola to Zika: GloPID-R in Action

The Ebola virus was a stark demonstration of how unprepared the world was to respond to infectious diseases outbreaks. GloPID-R offers coordinated solutions from identifying key research questions to pulling together experts. GloPID-R contributes to population protection during an epidemic by acting in three modes:

  1. Prepare: Funder and Research Network Connecting and Mapping Study & Readiness Plan

  2. Mobilize: Members, scientific advisory board, pool of experts, outbreak committee and ad-hoc working groups

  3. Respond: Funding calls and research capacities and capabilities summaries specific to the current epidemic i.e., Ebola, Zika, MERS-CoV, etc.

GloPID-R Responds to the Zika Outbreak

The Zika virus’s rapid spread and potential associated health consequences triggered GloPID-R members into action. With the Zika virus alert, GloPID-R members tested the Interim Readiness Plan for the first time. The plan is designed to rapidly activate research funders in the event of an outbreak. Very quickly after Brazil declared the Zika epidemic to be a public health emergency in November, the Outbreak Committee recommended that GloPID-R go into Readiness Plan’s “Response Mode.”

GloPID-R members compiled a report, “Zika Virus (ZIKV) Outbreak: Overview of Relevant Research, Projects and Expertise,” identifying research capacity and activities in the field of ZIKV and key research questions to be addressed. One of GloPID-R’s Brazilian Members, Instituto Fiocruz, was instrumental in providing information on Zika’s effects on the population from a regional perspective and the research challenges the virus poses.

As a next step, working groups have been organized by GloPID-R member institutions to cover the specific issues related to etiology, vaccines, diagnostics and data sharing.

About GloPID-R

GloPID-R is the only network of its kind to bring together research funding organizations on a global scale to facilitate an effective research response within 48 hours of a significant outbreak of a new or re-emerging infectious disease with pandemic potential.

Specific objectives of GloPID-R

  • Facilitate the exchange of information

  • Address scientific, legal, ethical and financial challenges

  • Implement a ‘One Health’ approach with close cooperation between human and animal health researchers

  • Establish a strategic agenda for research response

  • Connect infectious disease research networks

  • Actively involve developing countries

23 members and the WHO are engaged in GloPID-R

  • African Academy of Sciences (AAS), Africa – Represented by Berhanu Abegaz

  • Bill and Melinda Gates Foundation, USA – Represented by Penny Heaton

  • Canadian Institutes of Health Research (CIHR), Canada – Represented by Marc Ouellette

  • Consejo Nacional de Ciencia y Tecnología, Mexico – Represented by Jesus Arturo Borja Tamayo

  • European Commission – DG Research & Innovation, European Union – Represented by Line Matthiessen

  • German Federal Ministry for Education and Research (BMBF) / PT-DLR, Germany – Represented by Jeannette Endres-Becker

  • Indian Council of Medical Research (ICMR), India – Represented by Rashmi Arora

  • Institut de microbiologie et des maladies infectieuses (INSERM/IMMI), France – Represented by Jean-François Delfraissy

  • Instituto Butantan, Brazil – Represented by Marcelo Franco

  • Instituto Fiocruz, Brazil – Represented by Claudia Nunes Duarte dos Santos

  • Instituto de Salud Carlos III, Spain – Represented by Rafael de Andres Medina

  • International Development Research Centre (IDRC), Canada – Represented by Dominique Charron

  • Japan Agency for Medical Research and Development, Japan – Represented by Kensuke Nakajima

  • Ministry of Health, Italy – Represented by Gaetano Gugliemi

  • Ministry of Science, Technology and Productive Innovation, Argentina – Represented by Oscar-Daniel Salomon

  • National Health and Medical Research Council, Australia – Represented by Anne Kelso

  • National Research Foundation of Korea, South Korea – Represented by Kwang-Lae Hoe

  • Research Council of Norway (RCN), Norway – Represented by Jesper Simonsen

  • Sao Paulo Research Foundation (FAPESP), Brazil – Represented by Marilda Solon Teixera Bottesi

  • South African Medical Research Council, South Africa – Represented by Jeffrey Mphahlele

  • Thai National Institute of Health, Department of Medical Sciences, Thailand –Represented by Krisada Tharasook

  • U.S. Department of Health and Human Services, USA – Represented by Nicole Lurie

  • Wellcome Trust, United Kingdom – Represented by Jeremy Farrar

  • Observer organization: World Health Organization (WHO) – Represented by Bernadette Murgue

The secretariat of GloPID-R initiative is currently funded through the EU’s Horizon 2020 programme and is run by Fondation Mérieux (for the AVIESAN research network) together with the University of Oxford (for the ISARIC research network). The interim chair is the European Commission’s Directorate General for Research and Innovation, with Vice Chairs coming from Brazil, Canada, France and South Africa.

GloPID-R Media Contact

Koren Wolman-Tardy
Tel: +33 6 13 94 51 14
Email: koren.wolman-tardy@fondation-merieux.org

For more information on GloPID-R visit: http://www.glopid-r.org/

Top of Page

[]